{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T23:34:19Z","timestamp":1773876859387,"version":"3.50.1"},"reference-count":35,"publisher":"International Union Against Tuberculosis and Lung Disease","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["public health action"],"accepted":{"date-parts":[[2026,1,6]]},"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:sec>\n                    <jats:title>SETTING<\/jats:title>\n                    <jats:p>Sierra Leone has a high burden of drug-resistant TB (DR-TB), managed at three treatment centres.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>OBJECTIVE<\/jats:title>\n                    <jats:p>To compare treatment success between BPaL (bedaquiline, pretomanid, and linezolid)\/BPaLM (bedaquiline, pretomanid, linezolid, and moxifloxacin) and the standardised short and the individualised long regimens among DR-TB patients and identify predictors of unsuccessful outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>DESIGN<\/jats:title>\n                    <jats:p>Retrospective cohort study utilising routinely collected national DR-TB data from January 2022 to December 2024.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>Among 598 DR-TB patients registered from 2022 to 2024, 571 with complete outcomes were analysed. Overall treatment success was 80.2%, highest with BPaL\/BPaLM (87.1%) compared with the standardised short (78.8%) and individualised long regimens (70.4%). Adjusted analyses showed BPaL\/BPaLM remained strongly associated with higher success than the individualised long (adjusted risk ratio [aRR] 2.89; 95% confidence interval [CI] 1.80\u20134.64) and standardised short regimens (aRR 1.46; 95% CI 1.04\u20132.05). HIV co-infection and underweight body mass index independently predicted poor outcomes. Findings were consistent across propensity-weighted and sensitivity analyses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION<\/jats:title>\n                    <jats:p>Under routine programmatic conditions in Sierra Leone, BPaL\/BPaLM achieved higher treatment success than standardised short or individualised long regimens. However, HIV co-infection and undernutrition predicted poorer outcomes, underscoring the need for integrated nutritional support, expanded drug-susceptibility testing, and strengthened TB\/HIV services.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.5588\/pha.25.0056","type":"journal-article","created":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T16:09:03Z","timestamp":1773850143000},"page":"28-34","source":"Crossref","is-referenced-by-count":0,"title":["Evaluating treatment outcomes stratified by regimen among drug-resistant TB patients in Sierra Leone"],"prefix":"10.5588","volume":"16","author":[{"given":"J.A.","family":"Koroma","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.D.","family":"Fofanah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Nair","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.M.","family":"Kamau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.F.","family":"Kamara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.A.","family":"Sesay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.S.","family":"Turay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Sesay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Kanu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.K.","family":"Lahai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.S.","family":"Kanu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.T.","family":"Koroma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Fornah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.L.","family":"Seisay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.S.","family":"Bailor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Harding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Emezue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.B.","family":"Tefera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Ameh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Mazzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Lakoh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Mahmoud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3554","published-online":{"date-parts":[[2026,3,1]]},"reference":[{"key":"2026031809085751000_16.1.28.1","unstructured":"World Health Organization . The end TB strategy. Geneva: WHO, 2015."},{"key":"2026031809085751000_16.1.28.2","unstructured":"World Health Organization . Global TB report. Geneva: WHO, 2023."},{"key":"2026031809085751000_16.1.28.3","unstructured":"CDC . About drug-resistant tuberculosis disease. In: Tuberculosis (TB). Atlanta, GA, USA: Centres for Diseases Control and Prevention, 2024."},{"key":"2026031809085751000_16.1.28.4","unstructured":"CDC . Clinical overview of drug-resistant tuberculosis disease [internet]. In: Tuberculosis (TB). Atlanta, GA, USA: Centres for Diseases Control and Prevention, 2024. https:\/\/www.cdc.gov\/tb\/hcp\/clinical-overview\/drug-resistant-tuberculosis-disease.html."},{"key":"2026031809085751000_16.1.28.5","unstructured":"Programme GT . Types of TB drug-resistance [internet]. Geneva: WHO, 2024. https:\/\/www.who.int\/teams\/global-tuberculosis-programme\/diagnosis-treatment\/treatment-of-drug-resistant-tb\/types-of-tb-drug-resistance."},{"key":"2026031809085751000_16.1.28.6","unstructured":"World Health Organization . Implementing the end TB strategy: the essentials. Geneva: WHO, 2022. https:\/\/iris.who.int\/handle\/10665\/365364."},{"issue":"7","key":"2026031809085751000_16.1.28.7","doi-asserted-by":"crossref","first-page":"e0235843","DOI":"10.1371\/journal.pone.0235843","article-title":"Challenges of scaling-up of TB-HIV integrated service delivery in Ghana","volume":"15","author":"Anku","year":"2020","journal-title":"PLoS One"},{"key":"2026031809085751000_16.1.28.8","doi-asserted-by":"publisher","DOI":"10.7196\/samj.7689"},{"key":"2026031809085751000_16.1.28.9","doi-asserted-by":"publisher","DOI":"10.1179\/2047773215Y.0000000027"},{"issue":"3","key":"2026031809085751000_16.1.28.10","doi-asserted-by":"crossref","first-page":"255","DOI":"10.4103\/ijmy.ijmy_47_21","article-title":"Programmatic challenges in managing multidrug-resistant tuberculosis in Malawi","volume":"10","author":"Charlie","year":"2021","journal-title":"Int J Mycobacteriology"},{"key":"2026031809085751000_16.1.28.11","unstructured":"World Health Organization . WHO operational handbook on tuberculosis. Module 4: treatment - drug-resistant tuberculosis treatment, 2022 update. Geneva: WHO, 2022."},{"key":"2026031809085751000_16.1.28.12","unstructured":"World Health Organization . WHO consolidated guidelines on tuberculosis: module 4: treatment - drug-resistant tuberculosis treatment, 2022 update. Geneva: WHO, 2022."},{"key":"2026031809085751000_16.1.28.13","unstructured":"World Health Organization . Global tuberculosis report [internet]. Geneva: WHO, 2020. https:\/\/iris.who.int\/handle\/10665\/336069?search-result=true&query=TB+global+report+2020&scope=&rpp=10&sort_by=score&order=desc (Accessed 18 October 2024)."},{"key":"2026031809085751000_16.1.28.14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2007.11.008"},{"key":"2026031809085751000_16.1.28.15","unstructured":"Sesay AK . Early outcomes of bedaquiline\u2013pretomanid\u2013linezolid regimens in a high-burden setting: Sierra Leone national cohort, 2022\u20132023. West Afr J Med. 2024."},{"issue":"3","key":"2026031809085751000_16.1.28.16","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1093\/cid\/ciab1061","article-title":"Successful fidaxomicin hospital discharges of adult patients with clostridioides difficile infections post\u20132021 guidelines: are economic barriers finally coming down?","volume":"75","author":"Fang","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2026031809085751000_16.1.28.17","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01992-18"},{"key":"2026031809085751000_16.1.28.18","unstructured":"CIDRAP . New data support shorter regimen for resistant TB, 2021. https:\/\/www.cidrap.umn.edu\/new-data-support-shorter-regimen-resistant-tb (Accessed 13 November 2025)."},{"issue":"4","key":"2026031809085751000_16.1.28.19","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1093\/cid\/ciaf035","article-title":"The effectiveness and safety of bedaquiline, pretomanid, and linezolid (BPaL)\u2013Based regimens for rifampicin-resistant tuberculosis in non-trial settings\u2014a prospective cohort study in Belarus and Uzbekistan","volume":"81","author":"Sinha","year":"2025","journal-title":"Clin Infect Dis"},{"key":"2026031809085751000_16.1.28.20","doi-asserted-by":"crossref","unstructured":"Sridharan K , Sivaramakrishnan G . Efficacy of BPaL and BPaLM regimens in treating drug-resistant tuberculosis: a systematic review and meta-analysis. Am J Ther. 2025.","DOI":"10.1097\/MJT.0000000000001991"},{"key":"2026031809085751000_16.1.28.21","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1338902"},{"key":"2026031809085751000_16.1.28.22","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciad312"},{"issue":"1","key":"2026031809085751000_16.1.28.23","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s40794-025-00269-w","article-title":"Global research trends in BPaL and BPaLM regimens for drug-resistant tuberculosis: a bibliometric analysis","volume":"11","author":"Sridharan","year":"2025","journal-title":"Trop Dis Travel Med Vaccines"},{"key":"2026031809085751000_16.1.28.24","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1093\/cid\/ciad653","article-title":"Safety and tolerability of linezolid in novel short-course regimens containing bedaquiline, pretomanid, and linezolid to treat rifampicin-resistant tuberculosis: an individual patient data meta-analysis","volume":"78","author":"Hasan","year":"2024","journal-title":"Clin Infect Dis"},{"key":"2026031809085751000_16.1.28.25","unstructured":"TB Alliance . Historically successful global access campaign for pretomanid and BPaL-based regimens continues with major milestones in BRICS countries. Oxford, UK: Oxford University Press, 2025. https:\/\/www.tballiance.org\/historically-successful-global-access-campaign-for-pretomanid-and-bpal-based-regimens-continues-with-major-milestones-in-brics-countries\/."},{"issue":"1","key":"2026031809085751000_16.1.28.26","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3390\/antibiotics14010007","article-title":"Safety and effectiveness of BPaL-based regimens to treat multidrug-resistant TB: first experience of an Italian tuberculosis referral hospital","volume":"14","author":"Gualano","year":"2024","journal-title":"Antibiotics"},{"issue":"5","key":"2026031809085751000_16.1.28.27","doi-asserted-by":"crossref","first-page":"284","DOI":"10.5588\/ijtldopen.24.0524","article-title":"Treatment success rate and time to culture conversion under a prospective BPaL cohort study","volume":"2","author":"Burhan","year":"2025","journal-title":"IJTLD Open"},{"key":"2026031809085751000_16.1.28.28","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-021-05950-x"},{"key":"2026031809085751000_16.1.28.29","doi-asserted-by":"crossref","first-page":"1450669","DOI":"10.3389\/fnut.2024.1450669","article-title":"Undernutrition and its predictors among tuberculosis patients in Southwest Ethiopia","volume":"11","author":"Shifera","year":"2024","journal-title":"Front Nutr"},{"issue":"1","key":"2026031809085751000_16.1.28.30","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1186\/s13104-025-07268-2","article-title":"Impact of malnutrition and associated factors on rifampicin\/multi-drug-resistant tuberculosis treatment outcomes among patients treated in alert and St. Peter\u2019s Specialized Hospitals, Addis Ababa, Ethiopia: a retrospective follow-up study","volume":"18","author":"Siraj","year":"2025","journal-title":"BMC Res Notes"},{"key":"2026031809085751000_16.1.28.31","unstructured":"endTB . endTB clinical trial results (internet), 2023. https:\/\/endtb.org\/endtb-clinical-trial-results (Accessed 15 November 2025)."},{"issue":"5","key":"2026031809085751000_16.1.28.32","doi-asserted-by":"crossref","first-page":"e967","DOI":"10.1016\/S2214-109X(25)00021-X","article-title":"A roadmap for integrating nutritional assessment, counselling, and support into the care of people with tuberculosis","volume":"13","author":"Sinha","year":"2025","journal-title":"Lancet Glob Health"},{"key":"2026031809085751000_16.1.28.33","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2024-088629"},{"issue":"2","key":"2026031809085751000_16.1.28.34","doi-asserted-by":"crossref","first-page":"e0001357","DOI":"10.1371\/journal.pgph.0001357","article-title":"A scoping review of patient-centred tuberculosis care interventions: gaps and opportunities","volume":"3","author":"Myburgh","year":"2023","journal-title":"PLoS Glob Public Health"},{"issue":"3","key":"2026031809085751000_16.1.28.35","doi-asserted-by":"crossref","first-page":"319","DOI":"10.3390\/ijerph22030319","article-title":"Outcomes of treating tuberculosis patients with drug-resistant tuberculosis, human immunodeficiency virus, and nutritional status: the combined impact of triple challenges in rural Eastern Cape","volume":"22","author":"Dlatu","year":"2025","journal-title":"Int J Environ Res Public Health"}],"container-title":["Public Health Action"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.5588\/pha.25.0056","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T16:09:45Z","timestamp":1773850185000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.theunion.org\/lookup\/doi\/10.5588\/pha.25.0056"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,3,1]]},"published-print":{"date-parts":[[2026,3]]}},"alternative-id":["10.5588\/pha.25.0056"],"URL":"https:\/\/doi.org\/10.5588\/pha.25.0056","relation":{},"ISSN":["2220-8372"],"issn-type":[{"value":"2220-8372","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3]]}}}